Screener
Integra LifeSciences IART Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Long-term borrowings under senior credit facility | 1,736,105 | 1,729,556 |
| Long-term borrowings under securitization facility | 92,600 | — |
| Lease liability - operating leases | 162,660 | 163,059 |
| Deferred tax liabilities | 3,470 | 5,664 |
| Other liabilities | 194,397 | 204,278 |
| Total liabilities | 2,520,113 | 2,558,538 |
| Stockholders’ equity: | ||
| Preferred stock; no par value; 15,000 authorized shares; none outstanding | — | — |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's deferred tax assets?
- Integra LifeSciences (IART) reported deferred tax assets of $3.47M in Q2 2026.
- How has Integra LifeSciences's deferred tax assets changed year-over-year?
- Integra LifeSciences's deferred tax assets decreased by 94.2% year-over-year, from $60.06M to $3.47M.
- What is the long-term trend for Integra LifeSciences's deferred tax assets?
- Over 5 years (2020 to 2025), Integra LifeSciences's deferred tax assets has grown at a -18.9% compound annual growth rate (CAGR), from $16.19M to $5.66M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Integra LifeSciences's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude